Current Report Filing (8-k)
May 29 2020 - 7:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 29, 2020
AVEO Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-34655
|
|
04-3581650
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
30 Winter Street
Boston, Massachusetts
|
|
02108
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area
code: (857) 400-0101
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, $0.001 par value
|
|
AVEO
|
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01.
|
Regulation FD.
|
On May 29, 2020, AVEO Pharmaceuticals, Inc. (the Company) will host a conference call to discuss the final overall survival (OS)
results of its TIVO-3 trial, the Companys phase 3 trial of tivozanib in advanced renal cell carcinoma. A copy of the Companys slide presentation accompanying the conference call is attached as
Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 and in Exhibit 99.1 shall not
be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
On May 29, 2020, the Company issued a press release announcing the final OS results of its TIVO-3 trial. On
May 29, 2020, the Company also issued a press release announcing that the DEDUCTIVE trial, the Companys phase 1b/2 trial of tivozanib in combination with IMFINZI® (durvalumab) in
advanced hepatocellular carcinoma, has progressed to the phase 2 portion of the trial.
The full text of the press releases are attached as Exhibits 99.2
and 99.3 to this Current Report on Form 8-K.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
AVEO Pharmaceuticals, Inc.
|
|
|
|
Date: May 29, 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Michael Bailey
|
|
|
|
|
|
|
Michael Bailey
|
|
|
|
|
|
|
President and Chief Executive Officer
|
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Apr 2024 to May 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From May 2023 to May 2024